FDA Ok’d AstraZeneca’s Imjudo Plus Durvalumab for Liver Cancer

FDA approved AstraZeneca’s Tremelimumab(Imjudo) in combination with Durvalumab for adult patients with unresectable hepatocellular carcinoma, according to a statement on FDA website.

• Tremelimumab plus Durvalumab demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to sorafenib
• Median OS was 16.4 months versus 13.8 months
• Most common adverse reactions were rash, diarrhea, fatigue, pruritis, musculoskeletal pain and abdominal pain
• Tremelimumab was granted orphan drug designation

To view the source of this information, click here

To contact the reporter on this story:
Lin Cheng in New York at lcheng97@bloomberg.net

To contact the editor responsible for this story:
Chakradhar ...